Antibody Information
General Information of This Antibody
| Antibody ID | ANI0UDJCC |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | FAP hu36 |
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG1-kappa |
|||||
| Antigen Name | Prolyl endopeptidase FAP (FAP) |
Antigen Info | ||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
HPS157-039-001 [Investigative]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | Negative FAP expression (FAP-) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 2.5 mg/kg, qw*1.
|
||||
| In Vivo Model | Pancreatic adenocarcinoma PDX model (PDX: PAXF-736) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | Negative FAP expression (FAP-) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 2.5 mg/kg, qw*1.
|
||||
| In Vivo Model | Pancreatic adenocarcinoma PDX model (PDX: PAXF-736) | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
5.60 nM
|
Positive FAP expression (FAP+++/++) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Fibrosarcoma | HT-1080 cells (FAP expression) | CVCL_0317 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
10.33 nM
|
Negative FAP expression (FAP-) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Fibrosarcoma | HT-1080 cells (FAP expression) | CVCL_0317 | ||
HPS157-039-002 [Investigative]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 0.00% | Negative FAP expression (FAP-) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 2.5 mg/kg, qw*1.
|
||||
| In Vivo Model | Pancreatic adenocarcinoma PDX model (PDX: PAXF-736) | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
552.00 nM
|
Negative FAP expression (FAP-) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Fibrosarcoma | HT-1080 cells (FAP expression) | CVCL_0317 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
964.00 nM
|
Positive FAP expression (FAP+++/++) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Fibrosarcoma | HT-1080 cells (FAP expression) | CVCL_0317 | ||
HPS157-039-005 [Investigative]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 20.00% (Day 33) | Positive FAP expression (FAP+++/++) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 2.5 mg/kg, qw*1.
|
||||
| In Vivo Model | Pancreatic adenocarcinoma PDX model (PDX: PAXF-736) | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.96 nM
|
Negative FAP expression (FAP-) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Fibrosarcoma | HT-1080 cells (FAP expression) | CVCL_0317 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
555.00 nM
|
Positive FAP expression (FAP+++/++) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Fibrosarcoma | HT-1080 cells (FAP expression) | CVCL_0317 | ||
HPS157-039-004 [Investigative]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 70.00% (Day 33) | Positive FAP expression (FAP+++/++) | ||
| Method Description |
Mice were treated with an intravenous dose of the ADCs at 2.5 mg/kg, qw*1.
|
||||
| In Vivo Model | Pancreatic adenocarcinoma PDX model (PDX: PAXF-736) | ||||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
90.00 nM
|
Positive FAP expression (FAP+++/++) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Fibrosarcoma | HT-1080 cells (FAP expression) | CVCL_0317 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
108.00 nM
|
Negative FAP expression (FAP-) | ||
| Method Description |
Cells were incubated with increasing concentrations of each ADCs at 37°C for 6 days in complete culture medium.
|
||||
| In Vitro Model | Fibrosarcoma | HT-1080 cells (FAP expression) | CVCL_0317 | ||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.